P2B-053

CTRC Institute for Drug Development, University of Texas (San Antonio, TX) › P2B-053

P2B-053

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Phase II
CTRC Institute for Drug Development, University of Texas (San Antonio, TX) · Dr. Muller
consented 2012-11-21

completed

AEs

0

Serious

0

Dropout signal

–

Adverse events

0

No adverse events recorded. New events are triaged from the Safety tab.

Data queries

0

No data queries. Open queries would appear here for this patient.